BCL2 and cancer: In this study, our network pharmacology results showed that AKT1, AKT3, and BCL2 are hub targets, and KEGG pathway enrichment analysis revealed that PI3K-AKT signaling pathway is involved in the effect of Aloin A against cancer-related muscle atrophy.